Why the study?
Does telmisartan reduce glial activation and amyloid burden in in vitro and in vivo models of Alzheimer's disease?
Population
In vitro: BV2 microglia and primary neonatal rat glial cells. In vivo: 5X familial AD (5XFAD) mice.
Comparison
Telmisartan vs Perindopril in vivo; implied control in vitro
Design
Preclinical
Follow-up
up to two months (in vivo)
Authors
Loading...
Brain AT1R signaling may promote glial inflammation; leaves open translation to human cardiovascular outcomes.
Does telmisartan reduce glial activation and amyloid burden in in vitro and in vivo models of Alzheimer's disease?
Telmisartan reduces glial activation and amyloid burden in preclinical models of Alzheimer's disease, suggesting potential therapeutic benefits for neuroinflammation.
Torika et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: